Table 3 Number (and rate) of specific harm reduction interventions identified in provincial and territorial policy documents
Case (no. of documents within cases) | Harm reduction (unspecified) | Needle/syringe distribution | Naloxone | Supervised injection or consumption | Low-threshold opioid agonist treatment | Buprenorphine/naloxone (Suboxone) | Drug checking | Safer inhalation kits |
|---|---|---|---|---|---|---|---|---|
British Columbia (10) | 208 (20.8) | 31 (3.1) | 6 (0.6) | 22 (2.2) | 0 (0.0) | 1 (0.1) | 0 (0.0) | 3 (0.3) |
Alberta (4) | 78 (19.5) | 9 (2.3) | 0 (0.0) | 2 (0.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.3) |
Saskatchewan (3) | 253 (84.3) | 109 (36.3) | 0 (0.0) | 38 (12.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.3) |
Manitoba (7) | 80 (11.4) | 13 (1.9) | 1 (0.1) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 2 (0.3) |
Ontario (7) | 9 (1.3) | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Quebec (11) | 42 (3.8) | 11 (1.0) | 0 (0.0) | 17 (1.5) | 5 (0.5) | 0 (0.0) | 1 (0.1) | 0 (0.0) |
New Brunswick (1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Nova Scotia (4) | 63 (15.8) | 38 (9.5) | 2 (0.5) | 0 (0.0) | 1 (0.3) | 27 (6.8) | 0 (0.0) | 0 (0.0) |
Prince Edward Island (1) | 6 (6.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Newfoundland and Labrador (2) | 5 (2.5) | 2 (1.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Yukon (0) | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Northwest Territories (2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Nunavut (2) | 9 (4.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Canada (54) | 753 (13.9) | 214 (4.0) | 10 (0.2) | 81 (1.5) | 6 (0.1) | 28 (0.5) | 2 (0.04) | 7 (0.1) |